FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2200289340> ?p ?o ?g. }

• W2200289340 endingPage "5487" @default.
• W2200289340 startingPage "5480" @default.
• W2200289340 abstract "Abstract Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. Experimental Design: Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval &lt;365 days. Risk categories included low-risk (0–1 factor), mid-risk (2–3 factors), and high-risk (4–5 factors). Each test of association was conducted at the 5% level of significance. Logistic regression and survival analysis was used to determine whether factors were prognostic or could be used to guide therapy. Results: For the entire population (n = 452), high-risk patients had significantly worse OS (P &lt; 0.0001). The HRs of death for treating with topotecan in low-risk, mid-risk, and high-risk subsets are 1.18 [95% confidence interval (CI), 0.63–2.24], 1.11 (95% CI, 0.82–1.5), and 0.84 (95% CI, 0.50–1.42), respectively. The HRs of death for treating with bevacizumab in low-risk, mid-risk, and high-risk subsets are 0.96 (95% CI, 0.51–1.83; P = 0.9087), 0.673 (95% CI, 0.5–0.91; P = 0.0094), and 0.536 (95% CI, 0.32–0.905; P = 0.0196), respectively. Conclusions: This is the first prospectively validated scoring system in cervical cancer. The Moore criteria have real-world clinical applicability. Toxicity concerns may justify omission of bevacizumab in some low-risk patients where survival benefit is small. The benefit to receiving bevacizumab appears to be greatest in the moderate- and high-risk subgroups (5.8-month increase in median OS). Clin Cancer Res; 21(24); 5480–7. ©2015 AACR." @default.
• W2200289340 created "2016-06-24" @default.
• W2200289340 creator A5003548254 @default.
• W2200289340 creator A5009967316 @default.
• W2200289340 creator A5014611244 @default.
• W2200289340 creator A5022267430 @default.
• W2200289340 creator A5035607232 @default.
• W2200289340 creator A5046956876 @default.
• W2200289340 creator A5055050872 @default.
• W2200289340 creator A5072447565 @default.
• W2200289340 creator A5072505682 @default.
• W2200289340 creator A5077016336 @default.
• W2200289340 creator A5078849997 @default.
• W2200289340 creator A5089955620 @default.
• W2200289340 date "2015-12-14" @default.
• W2200289340 modified "2023-09-29" @default.
• W2200289340 title "Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study" @default.
• W2200289340 cites W1622646590 @default.
• W2200289340 cites W1932754573 @default.
• W2200289340 cites W1973753485 @default.
• W2200289340 cites W1974546699 @default.
• W2200289340 cites W2003187434 @default.
• W2200289340 cites W2003192634 @default.
• W2200289340 cites W2015989460 @default.
• W2200289340 cites W2019376439 @default.
• W2200289340 cites W2028070610 @default.
• W2200289340 cites W2042240304 @default.
• W2200289340 cites W2045849258 @default.
• W2200289340 cites W2050062343 @default.
• W2200289340 cites W2060764962 @default.
• W2200289340 cites W2074365882 @default.
• W2200289340 cites W2079730922 @default.
• W2200289340 cites W2085925328 @default.
• W2200289340 cites W2100756525 @default.
• W2200289340 cites W2118307358 @default.
• W2200289340 cites W2118508302 @default.
• W2200289340 cites W2126768246 @default.
• W2200289340 cites W2131538171 @default.
• W2200289340 cites W2152921325 @default.
• W2200289340 cites W2162833809 @default.
• W2200289340 cites W2170825221 @default.
• W2200289340 cites W2171725862 @default.
• W2200289340 cites W57754055 @default.
• W2200289340 doi "https://doi.org/10.1158/1078-0432.ccr-15-1346" @default.
• W2200289340 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4896296" @default.
• W2200289340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26672085" @default.
• W2200289340 hasPublicationYear "2015" @default.
• W2200289340 type Work @default.
• W2200289340 sameAs 2200289340 @default.
• W2200289340 citedByCount "55" @default.
• W2200289340 countsByYear W22002893402016 @default.
• W2200289340 countsByYear W22002893402017 @default.
• W2200289340 countsByYear W22002893402018 @default.
• W2200289340 countsByYear W22002893402019 @default.
• W2200289340 countsByYear W22002893402020 @default.
• W2200289340 countsByYear W22002893402021 @default.
• W2200289340 countsByYear W22002893402022 @default.
• W2200289340 countsByYear W22002893402023 @default.
• W2200289340 crossrefType "journal-article" @default.
• W2200289340 hasAuthorship W2200289340A5003548254 @default.
• W2200289340 hasAuthorship W2200289340A5009967316 @default.
• W2200289340 hasAuthorship W2200289340A5014611244 @default.
• W2200289340 hasAuthorship W2200289340A5022267430 @default.
• W2200289340 hasAuthorship W2200289340A5035607232 @default.
• W2200289340 hasAuthorship W2200289340A5046956876 @default.
• W2200289340 hasAuthorship W2200289340A5055050872 @default.
• W2200289340 hasAuthorship W2200289340A5072447565 @default.
• W2200289340 hasAuthorship W2200289340A5072505682 @default.
• W2200289340 hasAuthorship W2200289340A5077016336 @default.
• W2200289340 hasAuthorship W2200289340A5078849997 @default.
• W2200289340 hasAuthorship W2200289340A5089955620 @default.
• W2200289340 hasBestOaLocation W22002893401 @default.
• W2200289340 hasConcept C121608353 @default.
• W2200289340 hasConcept C126322002 @default.
• W2200289340 hasConcept C143998085 @default.
• W2200289340 hasConcept C188816634 @default.
• W2200289340 hasConcept C2776694085 @default.
• W2200289340 hasConcept C2777802072 @default.
• W2200289340 hasConcept C2778220009 @default.
• W2200289340 hasConcept C2780435969 @default.
• W2200289340 hasConcept C2781209748 @default.
• W2200289340 hasConcept C2908647359 @default.
• W2200289340 hasConcept C44249647 @default.
• W2200289340 hasConcept C50440223 @default.
• W2200289340 hasConcept C71924100 @default.
• W2200289340 hasConcept C99454951 @default.
• W2200289340 hasConceptScore W2200289340C121608353 @default.
• W2200289340 hasConceptScore W2200289340C126322002 @default.
• W2200289340 hasConceptScore W2200289340C143998085 @default.
• W2200289340 hasConceptScore W2200289340C188816634 @default.
• W2200289340 hasConceptScore W2200289340C2776694085 @default.
• W2200289340 hasConceptScore W2200289340C2777802072 @default.
• W2200289340 hasConceptScore W2200289340C2778220009 @default.
• W2200289340 hasConceptScore W2200289340C2780435969 @default.
• W2200289340 hasConceptScore W2200289340C2781209748 @default.
• W2200289340 hasConceptScore W2200289340C2908647359 @default.
• W2200289340 hasConceptScore W2200289340C44249647 @default.
• W2200289340 hasConceptScore W2200289340C50440223 @default.

• next